Health and social care
Psychedelic therapies are coming to Europe, but face barriers before reaching patients
Sep
The psychedelic medicine hype may be over, but the movement’s next act could be more important.
Prescriptions for psychedelic drugs are closer than ever for European patients grappling with complex mental health problems – but there are still a few thorny hurdles to contend with.
For decades, psychedelics like LSD, magic mushrooms, and MDMA (ecstasy or molly) have been known primarily as party drugs that elicit hallucinogenic states, after studies on their therapeutic potential ground to a halt in the 1970s in both Europe and North America.
Today psychedelics are once again entering the mainstream. Research has picked back up, many European psychiatrists are generally open to psychedelics in medical practice, and countries like Switzerland and Australia are making them available to patients on a limited basis.Psychedelic therapies are coming to Europe, but face barriers before reaching patients
